Achromatopsia Market

Market Overview:

The 7 major achromatopsia markets reached a value of US$ 106.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 181.4 Million by 2034, exhibiting a growth rate (CAGR) of 4.99% during 2024-2034.

The achromatopsia market has been comprehensively analyzed in IMARC's new report titled "Achromatopsia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Achromatopsia, also known as total color blindness, refers to a rare inherited eye disorder that affects an individual's ability to perceive colors. It is primarily caused by genetic mutations that impact the function of the cones in the retina, the light-sensitive cells responsible for color vision. As a result, individuals suffering from the illness experience complete or near-complete loss of color vision, seeing the world only in shades of black, white, and gray. The symptoms of achromatopsia include photophobia (extreme sensitivity to light), reduced visual acuity, and poor vision in bright lighting conditions. Due to the lack of color discrimination, patients often rely on contrast and brightness to navigate their surroundings. Diagnosing achromatopsia typically involves a comprehensive eye examination, visual acuity tests, and specialized color vision tests, such as the Farnsworth-Munsell 100 Hue Test, to assess color perception deficiencies. Genetic testing may also be conducted to identify specific gene mutations associated with the condition, aiding in confirming the diagnosis.

The increasing prevalence of mutations in genes like CNGA3, CNGB3, and GNAT2, which can lead to a lack of functional cone photoreceptor cells in the retina, is primarily driving the achromatopsia market. In addition to this, the rising utilization of specialized medications, such as carbonic anhydrase inhibitors and tinted lenses, that help to manage light sensitivity and reduce discomfort in individuals suffering from the ailment is creating a positive outlook for the market. Moreover, the widespread integration of physical and occupational therapies, as they focus on enhancing visual skills, adaptive techniques, and motor functions, is further bolstering the market growth. These procedures contribute to an improved quality of life and the development of essential abilities for daily living. Apart from this, the rising awareness and diagnosis of achromatopsia have fueled the market's expansion, prompting a surge in demand for effective treatments. Additionally, the adoption of innovative procedures, like optogenetics, which involves introducing light-sensitive proteins into the retina to restore vision, is also providing new avenues for treating the condition effectively. Furthermore, numerous advancements in gene therapy that aim to introduce functional genetic material into affected cells to correct the underlying genetic mutations are expected to drive the achromatopsia market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the achromatopsia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for achromatopsia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the achromatopsia market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the achromatopsia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the achromatopsia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current achromatopsia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the achromatopsia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the achromatopsia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the achromatopsia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of achromatopsia across the seven major markets?
• What is the number of prevalent cases (2018-2034) of achromatopsia by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of achromatopsia by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with achromatopsia across the seven major markets?
• What is the size of the achromatopsia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of achromatopsia?
• What will be the growth rate of patients across the seven major markets?
   

Achromatopsia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for achromatopsia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the achromatopsia market?
• What are the key regulatory events related to the achromatopsia market?
• What is the structure of clinical trial landscape by status related to the achromatopsia market?
• What is the structure of clinical trial landscape by phase related to the achromatopsia market?
• What is the structure of clinical trial landscape by route of administration related to the achromatopsia market?